Abstract 72P
Background
The PACIFIC trial established consolidation therapy with durvalumab as the standard of care for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) without progression after chemoradiotherapy (CRT), however, additional studies are still needed to further explore the optimal therapeutic strategies. Here, we reported the preliminary results of the phase 2 study of camrelizumab (an anti-PD-1 antibody) plus apatinib (an anti-angiogenic inhibitor targeting VEGFR2) as consolidation therapy after CRT in unresectable stage III NSCLC.
Methods
This was a multi-center, single-arm, phase 2 study done at seven sites in China. Adult pts with pathologically confirmed unresectable stage III NSCLC, an ECOG PS of 0 or 1, and no disease progression following platinum-based concurrent or sequential CRT received camrelizumab (200 mg, i.v., q3w) and apatinib (250 mg, orally, qd) until disease progression, unacceptable toxicity or for up to 12 months. The primary endpoint was progression-free survival (PFS).
Results
Between March 17, 2021 to July 17, 2023, 42 pts were enrolled. The median age was 61 years (range 26-78), with 39 pts (92.9%) being male and 31 (73.8%) having squamous NSCLC. According to RECIST 1.1, three (7.1%) of the 42 pts had a complete response and eight (19.0%) had a partial response, with the confirmed objective response rate of 26.2% (95% CI 13.9-42.0). Twenty-three pts (54.8%) had stable disease, with the disease control rate of 81.0 % (95% CI 65.9-91.4). As of August 28, 2023, the median follow-up was 11.4 months (95% CI 5.8-15.6). The median PFS was not reached (NR; 95% CI 11.4-NR), with the 6- and 12-month PFS rates of 88.8% (95% CI 72.8-95.7) and 68.6% (95% CI 47.4-82.7), respectively. The median overall survival was immature, with six deaths at data cutoff. Treatment-related adverse events (TRAEs) of grade 3-4 occurred in 18 pts (42.8%), with the most common being hypertension (21.4%), AST increased (7.1%) and hand-foot syndrome (4.8%). No grade 5 TRAEs occurred.
Conclusions
Camrelizumab plus apatinib as consolidation therapy showed preliminary activity in unresectable stage III NSCLC pts without disease progression after CRT, with no new safety signals.
Clinical trial identification
NCT04749394; February 11, 2021.
Legal entity responsible for the study
Cancer Hospital Chinese Academy of Medical Sciences.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ferdinandos Skoulidis
Session: Poster Display
159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors
Presenter: David Berz
Session: Poster Display
160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress
Presenter: Ignacio Melero
Session: Poster Display
164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma
Presenter: Anlin Li
Session: Poster Display
165P - Immunosuppressive F13A1+ Mo/M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers
Presenter: Jiahao Qu
Session: Poster Display
166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model
Presenter: Yan Zhou
Session: Poster Display
167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.
Presenter: Triparna Sen
Session: Poster Display
168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
Presenter: CATERINA DE ROSA
Session: Poster Display
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display